KAMADA LTD
KAMADA LTD logo
KMDA

KAMADA LTD (KMDA)

$4.62.13%

Market is closed
– opens on 8 PM, 12 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$4.56
Day's Range
$4.7
$4.11
52-Week Range
$6.96
1 month return4.55%
3 month return8.0%
1 year return29.23%
5 year return4.55%

Company Information

Kamada Ltd. (the 'Company') is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company's strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company's two leading commercial products are GLASSIA® and KEDRRAB®. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited ('Takeda') and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; a plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) and an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.
OrganizationKAMADA LTD
Employees355
CEOMr. Amir London
IndustryHealth Technology

Analyst Recommendation

based on 1 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 1 Wall street analysts offering stock ratings for KAMADA LTD(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 139.13%

Current

$4.6

Target

$11.0

Recommendation Trend

Based on 1 analyst

Current1M Ago3M Ago
Buy
1
6
6
Hold
0
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
210.6M
Book Value
$3.93
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.15
PEG Ratio
8.75
Wall Street Target Price
11.0

Valuation

Trailing PE0.0
Forward PE10.92
Price/Book (mrq)
1.22
Enterprise Value
198.8M
Enterprise Value/Revenue
1.72
Enterprise Value/Ebitda
67.31

Technicals

Beta
0.23
50 Day MA
4.5
200 Day MA
4.91

Institutional Holdings

State of Tennessee, Treasury Department

0.03%

Discover more

Frequently Asked Questions

What is KAMADA LTD share price today?

Can Indians buy KAMADA LTD shares?

How can I buy KAMADA LTD shares from India?

Can Fractional shares of KAMADA LTD be purchased?

What are the documents required to start investing in KAMADA LTD stocks?

What are today’s High and Low prices of KAMADA LTD?

What are today’s traded volumes of KAMADA LTD?

What is today’s market capitalisation of KAMADA LTD?

What is the 52 Week High and Low Range of KAMADA LTD?

How much percentage KAMADA LTD is down from its 52 Week High?

How much percentage KAMADA LTD is up from its 52 Week low?

What are the historical returns of KAMADA LTD?

Who is the Chief Executive Officer (CEO) of KAMADA LTD?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*